Cookies help us deliver our services. By using our services, you agree to our use of cookies. Click here to learn more

ImClone Photos

BioPharmaceutical Laboratory

+ Add Photo

ImClone Reviews

3.4
30 Reviews
Rating Trends
Recommend to a friend
Approve of CEO
(no image)
Jerry Kinzel
2 Ratings

ImClone Interviews

Interview Experience

Interview Experience

50%
33%
16%

Getting an Interview

Getting an Interview

52%
30%
17%

Interview Difficulty

2.8
Average

Interview Difficulty

Hard

Average

Easy
  1. Helpful (1)  

    Research Associate Interview

    Anonymous Employee
    Declined Offer
    Positive Experience
    Average Interview
    Declined Offer
    Positive Experience
    Average Interview

    Application

    I applied online. The process took a dayinterviewed at ImClone.

    Interview

    The itinerary and directions were emailed to me, I had communicated with HR back and forth using both email and phone. When I arrived onsite, the person greeting me was on time. The interview went according to schedule.

    Interview Questions

    • the most difficult question to answer was "why was I looking to leave my current job": I was not actively looking (pretty content, but when the opportunity came up I just decided to give it a try).   Answer Question

    Reasons for Declining

    The pay at the time was non-negotiable

ImClone Awards and Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.imclone.com
Headquarters Bridgewater, NJ
Size 1,000 to 5,000 Employees
Operated By Eli Lilly
Founded 1984
Type Subsidiary or Business Segment
Industry Biotech & Pharmaceutical
Revenue £50 to £100 million (GBP) per year

ImClone Systems wants to create identically successful cancer drug candidates. The company, a subsidiary of Eli Lilly, is focused on the development of oncology-related antibody therapies. The biotech research firm's only commercial product, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb (BMS) in North America and with Merck KGaA elsewhere. The company is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. It also... More

Work at ImClone? Share Your Experiences

ImClone

 
Click to Rate
or